2023
DOI: 10.1200/jco.2023.41.16_suppl.10591
|View full text |Cite
|
Sign up to set email alerts
|

Implementation of universal pan-cancer germline genetic testing in an Arab population: The jordanian exploratory cancer fenetics (Jo-ECAG) study.

Abstract: 10591 Background: Germline genetic testing (GGT) has a significant impact on cancer care. While universal testing has been selectively implemented in the U.S., less is known about adoption of this approach in other ethnic groups. This study reports on GGT results among newly diagnosed cancer patients (pts) in Jordan. Methods: Jo-ECAG was a prospective study of newly diagnosed cancer pts between April 2021 and September 2022 who underwent 84 gene GGT. Patients were classified based on the 2020 National Compreh… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
1
0
0
Order By: Relevance
“…We have recently completely one of the biggest germline genetic testing studies in the region, in which 3319 unselected Jordanian patients with any cancer (>50% were breast cancer) received germline genetic testing (GGT). In this study, and in many previous studies from our group [38], over 13% of Jordanian breast cancer patients tested as per the international guidelines had pathogenic or likely pathogenic variants [39].…”
Section: Germline Genetic Testingsupporting
confidence: 68%
“…We have recently completely one of the biggest germline genetic testing studies in the region, in which 3319 unselected Jordanian patients with any cancer (>50% were breast cancer) received germline genetic testing (GGT). In this study, and in many previous studies from our group [38], over 13% of Jordanian breast cancer patients tested as per the international guidelines had pathogenic or likely pathogenic variants [39].…”
Section: Germline Genetic Testingsupporting
confidence: 68%